| Patient | Diana Spencer |
|---|---|
| Date of birth | 1997-07-01 |
| Identifiers | MRN HR-ML028-SYN; SSN (made up) 000-28-5197 |
| Document date | 2026-11-01 |
| Author | Imogen Castleford, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
New patient visit at her own request for binge eating and vomiting: eating-disorder assessment, medical risk assessment, low potassium, mood, and safety planning. Concerns: She wants to stop the cycle of bingeing and vomiting, which she has kept secret and feels ashamed of; She has felt low, tired, and hopeless for some weeks; She is worried about her teeth and the swelling of her cheeks. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Potassium chloride 20 mEq extended-release oral tablet, one tablet by mouth twice daily with food | One tablet by mouth twice daily with food, swallowed whole with a full glass of water | Oral route | 2026-02-09 to 2026-03-16 | completed | S |
| Fluoxetine 20 mg oral capsule, one capsule by mouth each morning for one week, then two capsules each morning for one week | One capsule each morning for one week, then two capsules each morning for one week | Oral route | 2026-02-16 to 2026-03-02 | completed | S |
| Fluoxetine 60 mg oral tablet, one tablet by mouth each morning | One tablet by mouth each morning | Oral route | 2026-03-02 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Advance care planning conversation, about 16 minutes | 2026-04-13 to 2026-04-13 | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
No historical medical events are recorded.
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Concern | Status | Evidence |
|---|---|---|
| She wants to stop the cycle of bingeing and vomiting, which she has kept secret and feels ashamed of | active | S |
| She has felt low, tired, and hopeless for some weeks | active | S |
| She is worried about her teeth and the swelling of her cheeks | active | S |
Most recent measures: Leukocytes [#/volume] in Blood by Automated count 5.8 on 2026-02-09; Hemoglobin [Mass/volume] in Blood 12.9 on 2026-02-09; Platelets [#/volume] in Blood by Automated count 236 on 2026-02-09; Sodium [Moles/volume] in Serum or Plasma 140 on 2026-07-13; Potassium [Moles/volume] in Serum or Plasma 4.2 on 2026-07-13; Chloride [Moles/volume] in Serum or Plasma 103 on 2026-07-13; Carbon dioxide, total [Moles/volume] in Serum or Plasma 25 on 2026-07-13; Urea nitrogen [Mass/volume] in Serum or Plasma 19 on 2026-02-09; Creatinine [Mass/volume] in Serum or Plasma 0.8 on 2026-07-13; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 102 on 2026-07-13; Glucose [Mass/volume] in Serum or Plasma 81 on 2026-02-09; Calcium [Mass/volume] in Serum or Plasma 9.3 on 2026-02-09; Magnesium [Mass/volume] in Serum or Plasma 2 on 2026-03-16; Phosphate [Mass/volume] in Serum or Plasma 3.4 on 2026-02-09; Amylase [Enzymatic activity/volume] in Serum or Plasma 88 on 2026-05-11; Thyrotropin [Units/volume] in Serum or Plasma 1.8 on 2026-02-09; Q-T interval corrected 441 on 2026-03-16; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 4 on 2026-07-13; Total score [AUDIT-C] 1 on 2026-04-13 [S]
Strengths and supports: Works full time for charities that support homeless young people, people with disabilities, and people living with HIV; travels often for her work and enjoys meeting the people it serves; Supports: her friends and her work, which gives her purpose; she wants care that is kept private and decides who is told about her health [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Bulimia nervosa, severe: recurrent binge eating, each time with self-induced vomiting, averaging about ten episodes a week for about three years, hidden from everyone; self-worth tied closely to body shape and weight; no laxatives, diuretics, diet pills, or excessive exercise. SCOFF 4 of 5; EDE-Q global score 3.9. Findings: bilateral parotid enlargement, enamel erosion on the inner surfaces of the upper front teeth, calluses on the backs of two knuckles of the right hand, a pulse rise of 22 per minute on standing, low potassium and chloride with a raised bicarbonate, and a raised amylase; BMI 19.3. Synthetic modern episode linked to her own public account of bulimia | active | confirmed | F50.23 | S — Synthetic modern diagnosis by DSM-5-TR criteria; severity is graded by the average number of compensatory episodes a week (8 to 13 is severe). |
| Hypokalemia (potassium 3.1 mmol/L) with low chloride and metabolic alkalosis from repeated vomiting; QTc 452 ms; no palpitations, weakness, or fainting | resolved | confirmed | E87.6 | S — Synthetic presenting laboratory finding; resolved when potassium was normal on two checks. |
| Major depressive disorder, recurrent, moderate: about two months of low mood, tiredness, poor sleep, and feeling worthless and hopeless, with little pleasure in things she used to enjoy; PHQ-9 14 with item 9 scored 0; an earlier episode of depression after childbirth. Synthetic modern episode linked to her own public account of depression | active | confirmed | F33.1 | S — Synthetic modern diagnosis; the earlier episode is the post-natal depression she described publicly. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-02-09 | Leukocytes [#/volume] in Blood by Automated count | 5.8 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-02-09 | Hemoglobin [Mass/volume] in Blood | 12.9 | g/dL | 11.6-15 g/dL | Normal | S |
| 2026-02-09 | Platelets [#/volume] in Blood by Automated count | 236 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-02-09 | Sodium [Moles/volume] in Serum or Plasma | 137 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-02-09 | Potassium [Moles/volume] in Serum or Plasma | 3.1 | mmol/L | 3.5-5.1 mmol/L | Low | S |
| 2026-02-09 | Chloride [Moles/volume] in Serum or Plasma | 94 | mmol/L | 98-107 mmol/L | Low | S |
| 2026-02-09 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 32 | mmol/L | 22-29 mmol/L | High | S |
| 2026-02-09 | Urea nitrogen [Mass/volume] in Serum or Plasma | 19 | mg/dL | 7-20 mg/dL | Normal | S |
| 2026-02-09 | Creatinine [Mass/volume] in Serum or Plasma | 0.84 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-02-09 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 97 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-02-09 | Glucose [Mass/volume] in Serum or Plasma | 81 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-02-09 | Calcium [Mass/volume] in Serum or Plasma | 9.3 | mg/dL | 8.6-10.2 mg/dL | Normal | S |
| 2026-02-09 | Magnesium [Mass/volume] in Serum or Plasma | 1.8 | mg/dL | 1.7-2.2 mg/dL | Normal | S |
| 2026-02-09 | Phosphate [Mass/volume] in Serum or Plasma | 3.4 | mg/dL | 2.5-4.5 mg/dL | Normal | S |
| 2026-02-09 | Amylase [Enzymatic activity/volume] in Serum or Plasma | 146 | U/L | 28-100 U/L | High | S |
| 2026-02-09 | Thyrotropin [Units/volume] in Serum or Plasma | 1.8 | m[IU]/L | 0.45-4.5 mIU/L | Normal | S |
| 2026-02-09 | Q-T interval corrected | 452 | ms | Above 460 ms is prolonged in women | Normal | S |
| 2026-02-09 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 14 | {score} | S | ||
| 2026-02-09 | Total score [AUDIT-C] | 2 | {score} | S | ||
| 2026-02-16 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-02-16 | Potassium [Moles/volume] in Serum or Plasma | 3.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-02-16 | Chloride [Moles/volume] in Serum or Plasma | 99 | mmol/L | 98-107 mmol/L | Normal | S |
| 2026-02-16 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 28 | mmol/L | 22-29 mmol/L | Normal | S |
| 2026-02-16 | Creatinine [Mass/volume] in Serum or Plasma | 0.8 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-02-16 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 103 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-02-16 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 13 | {score} | S | ||
| 2026-03-16 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-03-16 | Potassium [Moles/volume] in Serum or Plasma | 3.9 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-03-16 | Chloride [Moles/volume] in Serum or Plasma | 101 | mmol/L | 98-107 mmol/L | Normal | S |
| 2026-03-16 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 26 | mmol/L | 22-29 mmol/L | Normal | S |
| 2026-03-16 | Creatinine [Mass/volume] in Serum or Plasma | 0.78 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-03-16 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 106 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-03-16 | Magnesium [Mass/volume] in Serum or Plasma | 2 | mg/dL | 1.7-2.2 mg/dL | Normal | S |
| 2026-03-16 | Q-T interval corrected | 441 | ms | Above 460 ms is prolonged in women | Normal | S |
| 2026-03-16 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 9 | {score} | S | ||
| 2026-04-13 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | {score} | S | ||
| 2026-04-13 | Total score [AUDIT-C] | 1 | {score} | S | ||
| 2026-05-11 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-05-11 | Potassium [Moles/volume] in Serum or Plasma | 4.1 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-05-11 | Chloride [Moles/volume] in Serum or Plasma | 102 | mmol/L | 98-107 mmol/L | Normal | S |
| 2026-05-11 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 25 | mmol/L | 22-29 mmol/L | Normal | S |
| 2026-05-11 | Creatinine [Mass/volume] in Serum or Plasma | 0.79 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-05-11 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 104 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-05-11 | Amylase [Enzymatic activity/volume] in Serum or Plasma | 88 | U/L | 28-100 U/L | Normal | S |
| 2026-05-11 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S | ||
| 2026-07-13 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-07-13 | Potassium [Moles/volume] in Serum or Plasma | 4.2 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-07-13 | Chloride [Moles/volume] in Serum or Plasma | 103 | mmol/L | 98-107 mmol/L | Normal | S |
| 2026-07-13 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 25 | mmol/L | 22-29 mmol/L | Normal | S |
| 2026-07-13 | Creatinine [Mass/volume] in Serum or Plasma | 0.8 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-07-13 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 102 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-07-13 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-02-09 | Body height | 178 | cm | S |
| 2026-02-09 | Body weight | 61 | kg | S |
| 2026-02-09 | Body mass index (BMI) [Ratio] | 19.3 | kg/m2 | S |
| 2026-02-09 | Systolic blood pressure | 102 | mm[Hg] | S |
| 2026-02-09 | Diastolic blood pressure | 64 | mm[Hg] | S |
| 2026-02-09 | Heart rate | 66 | /min | S |
| 2026-02-09 | Respiratory rate | 14 | /min | S |
| 2026-02-09 | Body temperature | 36.4 | Cel | S |
| 2026-02-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-02-16 | Body height | 178 | cm | S |
| 2026-02-16 | Body weight | 61.2 | kg | S |
| 2026-02-16 | Body mass index (BMI) [Ratio] | 19.3 | kg/m2 | S |
| 2026-02-16 | Systolic blood pressure | 104 | mm[Hg] | S |
| 2026-02-16 | Diastolic blood pressure | 66 | mm[Hg] | S |
| 2026-02-16 | Heart rate | 68 | /min | S |
| 2026-02-16 | Respiratory rate | 14 | /min | S |
| 2026-02-16 | Body temperature | 36.5 | Cel | S |
| 2026-02-16 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-03-16 | Body height | 178 | cm | S |
| 2026-03-16 | Body weight | 61.6 | kg | S |
| 2026-03-16 | Body mass index (BMI) [Ratio] | 19.4 | kg/m2 | S |
| 2026-03-16 | Systolic blood pressure | 106 | mm[Hg] | S |
| 2026-03-16 | Diastolic blood pressure | 66 | mm[Hg] | S |
| 2026-03-16 | Heart rate | 70 | /min | S |
| 2026-03-16 | Respiratory rate | 14 | /min | S |
| 2026-03-16 | Body temperature | 36.6 | Cel | S |
| 2026-03-16 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-05-11 | Body height | 178 | cm | S |
| 2026-05-11 | Body weight | 62 | kg | S |
| 2026-05-11 | Body mass index (BMI) [Ratio] | 19.6 | kg/m2 | S |
| 2026-05-11 | Systolic blood pressure | 108 | mm[Hg] | S |
| 2026-05-11 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 2026-05-11 | Heart rate | 68 | /min | S |
| 2026-05-11 | Respiratory rate | 14 | /min | S |
| 2026-05-11 | Body temperature | 36.6 | Cel | S |
| 2026-05-11 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-07-13 | Body height | 178 | cm | S |
| 2026-07-13 | Body weight | 62.1 | kg | S |
| 2026-07-13 | Body mass index (BMI) [Ratio] | 19.6 | kg/m2 | S |
| 2026-07-13 | Systolic blood pressure | 108 | mm[Hg] | S |
| 2026-07-13 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 2026-07-13 | Heart rate | 66 | /min | S |
| 2026-07-13 | Respiratory rate | 14 | /min | S |
| 2026-07-13 | Body temperature | 36.5 | Cel | S |
| 2026-07-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-04-13 | Body height | 178 | cm | S |
| 2026-04-13 | Body weight | 61.8 | kg | S |
| 2026-04-13 | Body mass index (BMI) [Ratio] | 19.5 | kg/m2 | S |
| 2026-04-13 | Systolic blood pressure | 106 | mm[Hg] | S |
| 2026-04-13 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 2026-04-13 | Heart rate | 68 | /min | S |
| 2026-04-13 | Respiratory rate | 14 | /min | S |
| 2026-04-13 | Body temperature | 36.6 | Cel | S |
| 2026-04-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-02-09 | New patient visit at her own request for binge eating and vomiting: eating-disorder assessment, medical risk assessment, low potassium, mood, and safety planning | finished | S |
| 2026-02-16 | One-week review: potassium recheck and eating disorders psychiatry consultation | finished | S |
| 2026-03-16 | Five-week review: potassium and ECG on fluoxetine 60 mg, CBT-E progress, mood, and safety | finished | S |
| 2026-05-11 | Three-month review: binge and purge frequency, electrolytes, dental care, mood, and safety | finished | S |
| 2026-07-13 | End-of-treatment review after 20 weeks of CBT-E: remission, relapse prevention, and continuing fluoxetine | finished | S |
| 2026-04-13 | Periodic adult preventive visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Medical risk assessment and monitoring for purging: orthostatic vital signs and weight at every visit, potassium, chloride, bicarbonate and creatinine weekly until potassium is normal twice and then at each visit, magnesium and phosphate at baseline and when potassium is low, an ECG at baseline and after any QT-relevant medicine change while potassium is low, and urgent or inpatient care for potassium below 3.0 mmol/L despite replacement, QTc above 500 ms, fainting, a pulse below 50, or blood in the vomit | completed | GL-APA-ED-2023, GL-NICE-NG69 | S |
| Eating disorders psychiatry consultation on the diagnosis and its severity, the right level of care, psychological treatment, fluoxetine, and medical monitoring | completed | GL-APA-ED-2023, GL-NICE-NG69 | S |
| Oral potassium chloride 20 mEq twice daily, with a recheck in one week; stopped once potassium is normal and vomiting is less frequent | completed | GL-NICE-NG69, GL-APA-ED-2023 | S |
| Nutrition: an eating disorders dietitian; regular eating of three meals and two or three snacks a day, no dieting or skipped meals, and no foods banned; caffeine cut down | completed | GL-NICE-NG69, GL-APA-ED-2023 | S |
| Dental protection while vomiting continues: no brushing for an hour after vomiting, a non-acid fluoride mouthwash, fewer acidic drinks, and a dental examination | completed | GL-NICE-NG69 | S |
| Structured safety assessment, a written safety plan with her warning signs, lethal-means counseling, the 988 Suicide & Crisis Lifeline, the PHQ-9 at each visit, and safety review at every visit | completed | GL-SUICIDE-2024, GL-CMID-2026, GL-USPSTF-DEP-2023 | S |
| Eating-disorder-focused cognitive behavioral therapy (CBT-E): 20 sessions over 20 weeks with an eating disorders therapist, twice weekly for the first four weeks, with weighing in session, self-monitoring records, regular eating, work on shape and weight concerns and on binges triggered by difficult feelings, and a written relapse-prevention plan at the end | completed | GL-APA-ED-2023, GL-NICE-NG69 | S |
| Fluoxetine started at 20 mg each morning and raised to 40 mg after one week and 60 mg after two weeks, for both the bulimia and the depression; ECG two weeks after reaching 60 mg; mood, sleep, agitation and suicidal thoughts checked at each visit; continued for at least a year after remission | completed | GL-APA-ED-2023, GL-CMID-2026 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| No binge eating or vomiting for at least four weeks by the end of 20 weeks of CBT-E | 2026-07-13 | completed | No binge eating or vomiting for six weeks | S |
| Potassium at least 3.5 mmol/L on two checks within four weeks | 2026-03-16 | completed | Potassium 3.6 and 3.9 mmol/L; supplement stopped | S |
| Regular eating (three meals and two or three snacks) on most days by three months | 2026-05-11 | completed | Regular eating on six or seven days a week | S |
| PHQ-9 score below 5 by the end of treatment | 2026-07-13 | completed | PHQ-9 4 | S |
| EDE-Q global score below 2.0 by the end of treatment | 2026-07-13 | completed | EDE-Q global score 1.6 | S |
Structured synthetic safety assessment on 2026-02-09: current ideation absent, intent absent, plan absent. Outpatient care with close follow-up. She has no current thoughts of suicide or self-harm and no self-injury now; past self-injury at a time of great distress is part of her history and was discussed with her gently. Eating disorders and depression both raise the risk of suicide and self-harm, so a written safety plan was made with her, with her own warning signs (a run of bad nights of bingeing, feeling hopeless, or wanting to hurt herself) and what to do about each, including whom to call. Lethal-means counseling: no firearm and no access to one; medicines are kept in small amounts. The 988 Suicide & Crisis Lifeline (call or text 988) was given and saved in her phone, with the clinic number. Safety reviewed at every visit [S]